[For Immediate Release]

中國抗體製藥有限公司

SinoMab BioScience Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3681)

SinoMab Received HKD6.5 Million Subsidy from HKSTP for the clinical study of atopic dermatitis ("AD")

(4 January 2024 – Hong Kong), SinoMab BioScience Limited ("SinoMab" or the **"Company"**, together with its subsidiaries, the "**Group**", stock code: **3681.HK)**, a Hong Kong listed biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative therapeutics for the treatment of immunological diseases, primarily mAb-based biologics, is pleased to announce that, the Company has received HK$6.5 million subsidy from the Hong Kong Science and Technology Parks Corporation ('HKSTP").

CTC program is offered by HKSTP Institute for Translational Research (ITR), the overarching aim is to provide a platform to transform Hong Kong and Greater Bay Area to become the go-to destination for translational medicine in the region. Under this program, funding support will be provided to biomedical companies of HKSTP to bring innovative, lifechanging therapies and technologies to patients.

SinoMab was granted with this CTC subsidy amount, embodying the recognition by the evaluation committee on the Company's product candidates and research and development (R&D) plan. SinoMab will carry out its clinical plan and progress for the clinical study of SM17, the Company's key product, for the treatment of atopic dermatitis (**"AD"**) with the subsidy of HK$6.5 million in the next 22 months.

SM17 is a novel, First-in-Class (**FIC**), humanized, IgG4-k monoclonal antibody, which is a global first-in-class monoclonal antibody drug targeting IL-25 receptor with the potential for treating atopic dermatitis, asthma, idiopathic pulmonary fibrosis and other immunological disorders. SM17 could suppress Type 2 helper T (Th2) immune responses by binding to IL-25 receptor (also known as IL-17RB) on Type 2 Innate Lymphoid cells (ILC2s) and Th2 cells, to block a cascade of responses induced by IL-25 and suppress the release of the downstream Th2 cytokines such as IL-4, IL-5 and IL-13. IL-25 is a critical cytokine classified as ''alarmin'', which has shown to be implicated in the pathogenesis of autoimmune and inflammatory skin diseases, especially in AD. Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index and

patient's quality of life, but patients showing irresponsiveness to those approved therapies still need effective products to make up for the unmet medical needs.

We are accelerating studies for SM17. In the United States, a Phase I study for SM17 had been completed, with the Last Subject Last Visit (**LPLV**) completed in September 2023. The clinical study report is expected to be released by the first quarter of 2024. As of today, no drug-related serious adverse event has been reported; In China, following the granting of Investigational New Drug (**''IND''**) approval of SM17 for the treatment of AD and asthma by the National Medical Products Administration of China (**the ''NMPA''**) on 8 September 2023 and 11 August 2023 respectively, the Company has also successfully completed the first cohort of the healthy subjects in a phase I clinical trial of SM17 in China on 25 November 2023. As at present, no adverse event was observed.

Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab said that: "We are very happy and honored to receive the subsidy from CTC program of HKSTP. We are grateful for the long-term support and assistance of the HKSTP in promoting innovation and development of local biopharmaceutical companies. The granting of subsidy from HKSTP could greatly support and accelerate our clinical program and development of SM17. This may possibly bring a new treatment option to AD patients who show irresponsiveness to those approved therapies, and to make up the unmet medical needs. We will continue to speed up the realization of product commercialization, adhere to the concept of independent innovation, strive for the well-being of patients and create value for shareholders."

About SinoMab BioScience Limited

SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company's flagship product Suciraslimab (SM03) is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer's disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.

This press release is issued by **SinoMab BioScience Limited**. For further information, please contact:

Financial PR (HK) Limited

Contact: Ms. Chloe Chiu / Ms. Serena Zhang / Ms. Romy Hong
Email: sinomab@financialpr.hk
Tel: (852) 2610 0846 Fax: (852) 2610 0842